Research Analysts Offer Predictions for DWTX Q3 Earnings

Dogwood Therapeutics, Inc (NASDAQ:DWTX) – Equities researchers at HC Wainwright raised their Q3 2025 EPS estimates for shares of Dogwood Therapeutics in a research note issued to investors on Tuesday, September 30th. HC Wainwright analyst S. Lee now forecasts that the company will earn ($0.45) per share for the quarter, up from their prior forecast of ($0.47). HC Wainwright currently has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($6.43) per share. HC Wainwright also issued estimates for Dogwood Therapeutics’ Q4 2025 earnings at ($0.48) EPS, FY2025 earnings at ($0.01) EPS, Q1 2026 earnings at ($0.53) EPS, Q2 2026 earnings at ($0.58) EPS, Q3 2026 earnings at ($0.65) EPS, Q4 2026 earnings at ($0.72) EPS, FY2026 earnings at ($2.48) EPS, FY2027 earnings at ($3.14) EPS, FY2028 earnings at ($3.29) EPS and FY2029 earnings at $1.12 EPS.

Dogwood Therapeutics (NASDAQ:DWTX) last issued its earnings results on Wednesday, August 13th. The company reported ($1.99) EPS for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.73).

Dogwood Therapeutics Price Performance

Shares of DWTX opened at $6.42 on Thursday. The company has a market cap of $12.26 million, a P/E ratio of -0.34 and a beta of 1.89. The stock has a fifty day moving average price of $5.10 and a 200 day moving average price of $4.98. Dogwood Therapeutics has a 12 month low of $1.62 and a 12 month high of $29.28.

Institutional Trading of Dogwood Therapeutics

An institutional investor recently bought a new position in Dogwood Therapeutics stock. FNY Investment Advisers LLC purchased a new position in shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 12,500 shares of the company’s stock, valued at approximately $62,000. FNY Investment Advisers LLC owned 0.65% of Dogwood Therapeutics as of its most recent filing with the Securities and Exchange Commission. 9.05% of the stock is currently owned by institutional investors and hedge funds.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics, Inc is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia.